Overview

Paras Biopharmaceuticals Finland Oy is committed to innovation and high quality products and technology. Paras Biopharmaceuticals Finland Oy has developed robust biosimilars technologies for the following products.

Our technology and biopharma API products cater for the following:
Paras Biosimilars Technologies / API
Category
Product/ Biosimilars Technology
Technology Platform
Osteoporosis PB Osteo-1010 (Biosimilar) Diabrid Technology / NobleCleav® Technology
Rheumatoid Arthritis PB (RA)- 2010 ( Biosimilar) High Expression Technology
Metabolic Disorders PB (MDT)- 3010 (Biosimilar) Diabrid Technology / NobleCleav® Technology
Metabolic Disorders PB (MDT)- 3020 ( Biosimilar) Diabrid Technology / NobleCleav® Technology
Metabolic Disorders PB (MDT)- 3030 ( Biosimilar) High Expression Technology
Metabolic Disorders PB (MDT)- 3040 ( Biosimilar) Diabrid Technology / NobleCleav® Technology
Oncology PPB (CT)- 4010 Under Development
Oncology PB (CT)- 4020 Under Development
Disclaimer

Products under patents are part of our research projects. These products may be offered only in those countries where patents have expired.

For the latest status, please contact Paras Biopharmaceuticals Finland Oy.